Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Q1 2024 Blueprint Medicines Corp Earnings Call Transcript

May 02, 2024 / 12:00PM GMT
Release Date Price: $107 (+12.80%)
Operator

Good morning. My name is Faye, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines first quarter 2024 financial results conference call. (Operator instructions) Thank you. Jenna Cohen, you may begin your conference.

Jenna Cohen
Blueprint Medicines Corp - Senior Director & Head of IR

Thanks, Faye, and good morning, everyone. Welcome to Blueprint Medicines first quarter 2024 financial and operating results conference call. This morning, we issued a press release which outlines the topics we plan to discuss today. You can access the press release as well as the slides that will be reviewing today by going to the Investors section of our website at www.Blueprint Medicines.com.

Joining me today are Kate Haviland, Chief Executive Officer; Philina Lee, Chief Commercial Officer; Fouad Namouni, President, Research and Development; and Mike Landsittel, Chief Financial Officer. Christy Rossi, Chief Operating Officer; and Becker Hewes, Chief Medical Officer, are also on the line and available

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot